39 of 79 (49.4%) germline BRCA1/2 mutant patients with advanced cancers developed RDR while receiving PARP inhibitor monotherapy, versus 7 of 34 (20.6%) patients with unknown or wildtype BRCA1/2 status (RR: 2.70,95% CI 1.40-6.50, p=0.004). This evidence concerns the gene BRCA1 and cancer.